Physician profile
John Barth
NPI 1184314536
$1,577.18
in general payments reported to CMS, 2019-2025
11 companies · $281 in 2025
The $281 reported for 2025 was more than what 83% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $501 · 2024: $795 · 2025: $281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,563 · Education: $13.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,563.42 |
| Education | $13.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $381.42 | 2023-2025 | |
| Genzyme Corporation | $337.64 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $317.46 | 2023-2024 | Dupixent |
| Janssen Biotech, INC. | $152.98 | 2024 | Tremfya, Stelara |
| Heron Therapeutics, INC. | $125.00 | 2025 | Zynrelef |
| Qol Medical, LLC | $86.17 | 2023-2025 | Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $78.38 | 2023-2024 | Gattex, Eohilia |
| Mirum Pharmaceuticals, INC. | $46.10 | 2023-2025 | Cholbam, Livmarli |
| Sobi, INC | $23.67 | 2025 | |
| Ironwood Pharmaceuticals, INC | $15.28 | 2024 | |
| Sandoz INC. | $13.08 | 2024 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Barth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.